CLINICOPATHOLOGICAL CRITERIA AND SURGICAL OPTIONS FOR PATIENTS WITH OPERABLE EXTREMITIES SOFT TISSUE SARCOMA Tarek El favoumi, Ahmed Abdeladif, Mahmoud Alhussini, Abdigani A.A

Department of surgery, Faculty of medicine, Alexandria University

Introduction

Heterogenous group of tumors like Soft Tissue Sarcoma, in all pediatric and adult malignancies make around 12% and 1% respectively. As per the Egyptian National Population-Based Cancer Registry Program in the year 2008-2011, 1.47% of all cases were STSs. Extremities being the ones frequently affected, they make around 59% of all sarcomas. The median age of onset is from 50-55 years with no ethnic/race predisposition. Soft Tissue Sarcoma in comparison to other tumors has got its own unique features that up until today has made the understanding of this disease quite unclear and these are:- 1) The rarity of the disease. 2) The numerous histopathological subtypes. 3) Complex biological behavior. 4) Anatomical sites involvement

Aim of the work

The aim of the work was to identify the pathological subtypes, criteria, and surgical options adopted for managing operable soft tissue sarcoma of the extremities.

Methods

Immediately after obtaining a consent from the ethical committee of Alexandria University Faculty of medicine, the patients' clinical details, pathological pattern of the disease and management modalities were obtained from the patients' files. All the patients in the study had operable soft tissue sarcoma and they underwent surgical interventions.

Results

Surgery type (limb sparing or amputation) in relation to the different types of parameters like gender, age, limb involved, site, histological subtype, tumor size, stage, follow-up and outcome results were found not to be statistically significant. A univariate analysis on the parameters affecting the type of surgery has showed that a combination of chemotherapy and radiotherapy and the stage of the disease significantly affected the type of surgery. (univariate P value of 0.023 and 0.039 respectively).

	1					1 1		Univariate		#Multivariate		
	Surger Limb sparing (n =54)		ry types Amputation (n = 7)		c2	р		OR(95C.I)	р	OR(95C.I)	р	
							Gender	0.870 (0.177-4.265)	0.864			
							Age	0.693 (0.328–1.463)	0.336			
	No. %	No.	%			Family history	$2x10^8(0.0)$	1.000				
Gender						1 1	Limb involved	0.800 (0.141-4.534)	0.801			
Male	29	53.7	4	57.1	0.030	^{FE} p=	Histologic type					
Female	25	46.3	3	42.9		1.000	Lip sarcoma	1.000	0.864			
Age (years)							Synovial sarcoma	1.857 (0.213-16.179)	0.575			
20-≤40	24	44.4	5	71.4		MC		0 650(0 081 5 206)	0.685			
$40 - \le 60$	25	46.3	2	28.6	1.433	^{мс} р= 0.578	MPNST	0.650(0.081-5.206)	0.085			
> 60	5	9.3		0.0			MFH	2.167 (0.144-32.528)	0.576			
Limb involved							Others	0.999(0.0-0.0)	0.999			
Lower limb	36	66.7	5	71.4	0.064	^{FE} p=	Tumor size	2.101 (0.966–4.570)	0.061			
Upper limb	18	33.3	2	28.6		1.000	Grade		0.001			
Site						1 1	Grade 1 ®`	_	_			
Thigh	26	48.1	1	14.3	7.317	^{мс} р= 0.114	Grade 2	$1x10^{8}(0.0)$	0.999			
Leg	7	13.0	4	57.1			Grade 3	$3x10^8(0.0)$	0.998			
Gluteal	3	5.6	0	0.0			Neoadjuvant					
Arm	9	16.7		14.3			Not given ®	-	_		0.124	
Forearm	6	11.1	1	14.3			Chemotherapy	2.333 (0.216–25.245)	0.486	1.470(0.118-18.258)	0.764	
Shoulder	3	5.6	0	0.0			Chemo +Radio	0.104 (0.015–0.735)	0.023*	0.166(0.022-1.246)	0.081	
Histologic type		0.0	Ť	0.0			Stage	3.719(1.066–12.975)	0.039*	3.020 (0.690-13.211)	0.142	
Liposarcoma	11	20.4	0	0.0	3.781		Outcome					
Others	13	24.1	2	28.6		^{мс} р= 0.376	Survived®	-	-			
synovial sarcoma	13	13.0	$\frac{2}{2}$	28.6			Lost to follow-up	0.396 (0.044–3.559)	0.408			
MFH (UPS)	20	37.0	2	28.6					•			
MPNST	3	5.6		14.3				Concl	lusion			
Tumor size	5	5.0		14.3		+						
< 5cm	14	25.9	0	0.0					.1 1		× .1•	
>5 - < 10 cm	25	46.3	3	42.9		^{мс} р= 0.203	The commonest	extremity affected	was the lower	extremity (62.7%), thi	
> 10 - < 15 cm	6	11.1		14.3	3.975		being the comr	monest site (44.3)	% and Undi	fferentiated Pleo	morph	
> 10 = < 15 cm	9	16.7		42.9		0.203	Sarcoma was the	Sarcoma was the commonest pathological subtype (36.1) %.				
Stage	9	10.7	5	42.9		+		-	• • • •		no ond	
IA	6	11.1	0	0.0				ltimate treatment of				
IB	10	18.5		0.0			limb sparing pro	ocedure should alw	vays be consid	ered, unless the	tumor	
IB II	8	18.3		0.0	4.605	^{мс} р=0.247	not amenable to	a limb salvaging te	chnique.			
IIIA	8 19	35.2		42.9		P=0.247		djuvant chemo-rad	-	instages the tumo	or hen	
IIIA IIIB	19	20.4		42.9 57.1				•	. .	•		
Follow-up period (months)	11	20.4	+	57.1		+	U U	ances of a patient	0 0		•	
<12 month	17	31.5	1	14.3	2.491		disease is also in	nportant in determi	ining the type of	ofsurgical interver	ntion t	
<12 month	17	18.5		0.0		мср=0.335	patient will unde	ergo.				
> 24 month	27	50.0		0.0 85.7		p=0.555	Parlone will and	-0-				
	21	50.0	0	03.7			100.00		2021 @Alex:	andria Faculty of M	Aedicir	
							1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		A A A A A A A A A A A A A A A A A A A			
Outcome Survived	38	70.4	6	85.7		^{FE} p=	ALEXA	NDRIA		CC-BY-NC		

